Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Protara Therapeutics in a note issued to investors on Monday, March 17th. Cantor Fitzgerald analyst L. Watsek forecasts that the company will post earnings of ($1.62) per share for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Protara Therapeutics' current full-year earnings is ($3.32) per share.
Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its quarterly earnings data on Wednesday, March 12th. The company reported ($0.48) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.09.
A number of other brokerages have also recently issued reports on TARA. Lifesci Capital assumed coverage on shares of Protara Therapeutics in a report on Tuesday, March 11th. They set an "outperform" rating and a $22.00 price objective for the company. HC Wainwright restated a "buy" rating and issued a $23.00 price objective on shares of Protara Therapeutics in a research report on Thursday, March 6th. Finally, Guggenheim reaffirmed a "buy" rating and set a $20.00 price objective on shares of Protara Therapeutics in a research note on Friday, December 6th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Protara Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $22.50.
View Our Latest Research Report on TARA
Protara Therapeutics Trading Down 0.4 %
Shares of TARA stock traded down $0.02 on Wednesday, reaching $4.60. The company had a trading volume of 836,802 shares, compared to its average volume of 793,498. The stock has a market cap of $169.13 million, a PE ratio of -1.63 and a beta of 1.69. The company has a 50-day moving average of $4.29 and a 200-day moving average of $3.57. Protara Therapeutics has a 12 month low of $1.60 and a 12 month high of $10.48.
Institutional Investors Weigh In On Protara Therapeutics
Several institutional investors have recently added to or reduced their stakes in TARA. HBK Investments L P bought a new stake in shares of Protara Therapeutics in the fourth quarter valued at about $106,000. Squarepoint Ops LLC acquired a new stake in Protara Therapeutics in the 4th quarter valued at $110,000. Dimensional Fund Advisors LP bought a new stake in Protara Therapeutics during the fourth quarter worth about $111,000. Bailard Inc. acquired a new position in Protara Therapeutics during the fourth quarter valued at approximately $157,000. Finally, XTX Topco Ltd acquired a new position in shares of Protara Therapeutics during the 3rd quarter worth approximately $60,000. 38.13% of the stock is owned by institutional investors.
About Protara Therapeutics
(
Get Free Report)
Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Read More

Before you consider Protara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protara Therapeutics wasn't on the list.
While Protara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.